Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 247

Similar articles for PubMed (Select 12171517)

1.

Selective inhibition of osteoclast vacuolar H(+)-ATPase.

Farina C, Gagliardi S.

Curr Pharm Des. 2002;8(23):2033-48. Review.

PMID:
12171517
2.

Novel bone antiresorptive agents that selectively inhibit the osteoclast V-H+-ATPase.

Farina C, Gagliardi S, Nadler G, Morvan M, Parini C, Belfiore P, Visentin L, Gowen M.

Farmaco. 2001 Jan-Feb;56(1-2):113-6. Review.

PMID:
11347950
3.
4.

Diphyllin, a novel and naturally potent V-ATPase inhibitor, abrogates acidification of the osteoclastic resorption lacunae and bone resorption.

Sørensen MG, Henriksen K, Neutzsky-Wulff AV, Dziegiel MH, Karsdal MA.

J Bone Miner Res. 2007 Oct;22(10):1640-8.

PMID:
17576165
5.

A selective inhibitor of the osteoclastic V-H(+)-ATPase prevents bone loss in both thyroparathyroidectomized and ovariectomized rats.

Visentin L, Dodds RA, Valente M, Misiano P, Bradbeer JN, Oneta S, Liang X, Gowen M, Farina C.

J Clin Invest. 2000 Jul;106(2):309-18.

6.

Structure and function of V-ATPases in osteoclasts: potential therapeutic targets for the treatment of osteolysis.

Xu J, Cheng T, Feng HT, Pavlos NJ, Zheng MH.

Histol Histopathol. 2007 Apr;22(4):443-54. Review.

PMID:
17290355
7.

(2Z,4E)-5-(5,6-dichloro-2-indolyl)-2-methoxy-N-(1,2,2,6,6- pentamethylpiperidin-4-yl)-2,4-pentadienamide, a novel, potent and selective inhibitor of the osteoclast V-ATPase.

Nadler G, Morvan M, Delimoge I, Belfiore P, Zocchetti A, James I, Zembryki D, Lee-Rycakzewski E, Parini C, Consolandi E, Gagliardi S, Farina C.

Bioorg Med Chem Lett. 1998 Dec 15;8(24):3621-6.

PMID:
9934482
8.
9.

The vacuolar ATPase in bone cells: a potential therapeutic target in osteoporosis.

Yuan FL, Li X, Lu WG, Li CW, Li JP, Wang Y.

Mol Biol Rep. 2010 Oct;37(7):3561-6. doi: 10.1007/s11033-010-0004-7. Epub 2010 Feb 25. Review.

PMID:
20182803
10.

5-(5,6-Dichloro-2-indolyl)-2-methoxy-2,4-pentadienamides: novel and selective inhibitors of the vacuolar H+-ATPase of osteoclasts with bone antiresorptive activity.

Gagliardi S, Nadler G, Consolandi E, Parini C, Morvan M, Legave MN, Belfiore P, Zocchetti A, Clarke GD, James I, Nambi P, Gowen M, Farina C.

J Med Chem. 1998 May 7;41(10):1568-73.

PMID:
9572882
11.

V-ATPases in osteoclasts: structure, function and potential inhibitors of bone resorption.

Qin A, Cheng TS, Pavlos NJ, Lin Z, Dai KR, Zheng MH.

Int J Biochem Cell Biol. 2012 Sep;44(9):1422-35. doi: 10.1016/j.biocel.2012.05.014. Epub 2012 May 29. Review.

PMID:
22652318
12.

A rationale for osteoclast selectivity of inhibiting the lysosomal V-ATPase a3 isoform.

Nyman JK, Väänänen HK.

Calcif Tissue Int. 2010 Sep;87(3):273-83. doi: 10.1007/s00223-010-9395-7. Epub 2010 Jul 2.

PMID:
20596699
13.

A pharmacological assessment of the mammalian osteoclast vacuolar H(+)-ATPase.

Hall TJ, Schaueblin M.

Bone Miner. 1994 Nov;27(2):159-66.

PMID:
7711523
14.
15.

Specific biological functions of vacuolar-type H(+)-ATPase and lysosomal cysteine proteinase, cathepsin K, in osteoclasts.

Sahara T, Itoh K, Debari K, Sasaki T.

Anat Rec A Discov Mol Cell Evol Biol. 2003 Feb;270(2):152-61.

16.

Disruption of the V-ATPase functionality as a way to uncouple bone formation and resorption - a novel target for treatment of osteoporosis.

Thudium CS, Jensen VK, Karsdal MA, Henriksen K.

Curr Protein Pept Sci. 2012 Mar;13(2):141-51. Review.

PMID:
22044152
17.

The osteoclast proton pump differs in its pharmacology and catalytic subunits from other vacuolar H(+)-ATPases.

Chatterjee D, Chakraborty M, Leit M, Neff L, Jamsa-Kellokumpu S, Fuchs R, Bartkiewicz M, Hernando N, Baron R.

J Exp Biol. 1992 Nov;172:193-204.

19.

Synthesis and structure-activity relationships of bafilomycin A1 derivatives as inhibitors of vacuolar H+-ATPase.

Gagliardi S, Gatti PA, Belfiore P, Zocchetti A, Clarke GD, Farina C.

J Med Chem. 1998 May 21;41(11):1883-93.

PMID:
9599238
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk